A phase II/III study of trans sodium crocetinate (TSC) in the treatment of pancreatic cancer.

Trial Profile

A phase II/III study of trans sodium crocetinate (TSC) in the treatment of pancreatic cancer.

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Transcrocetinate sodium (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Mar 2016 According to a Diffusion Pharmaceuticals media release, the company is planning to commence this trial in the first half of 2017.
    • 14 Jan 2016 According to a Diffusion Pharmaceuticals media release, the company is planning to commence a phase II/III trial in pancreatic cancer in 2016.
    • 14 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top